Data from the SWOG 1826 trial shows that nivolumab+AVD improves progression-free survival across all evaluated subgroups, including by age, disease stage, and risk score. This broad efficacy simplifies clinical decision-making, establishing it as a new standard for advanced-stage disease.

In the EV+pembrolizumab combination, if a patient achieves an excellent response but develops prohibitive EV-related toxicities like neuropathy, a viable strategy is to discontinue EV and maintain the patient on pembrolizumab monotherapy. This can sustain the response while improving quality of life.

Even if randomized trials show zongertinib's efficacy is merely comparable to chemoimmunotherapy, its significantly milder safety profile—especially its lack of cardiac toxicity and manageable side effects—is expected to make it the preferred first-line choice. Patient quality of life and tolerability are becoming decisive factors in treatment selection.

The adoption of nivolumab+AVD in community oncology is streamlined because practitioners are already experienced with managing immune-related adverse events from using checkpoint inhibitors in various solid tumors. This existing familiarity flattens the learning curve for this new lymphoma regimen.

Though ADCs like Sacituzumab Govitekan cause notable side effects like diarrhea and neutropenia, patient-reported outcome data shows they provide a meaningful and sustained improvement in quality of life compared to standard chemotherapy. This was observed even with longer treatment durations and lower discontinuation rates.

While severe (Grade 3+) neuropathy from enfortumab vedotin is rare, oncologists emphasize that Grade 2 toxicity is common and significantly impairs patients' quality of life. This 'moderate' side effect is often painful and interferes with daily activities, warranting an immediate hold on treatment, not just waiting for Grade 3.

A key principle for clinicians is that an antibody-drug conjugate's adverse events are primarily dictated by its linker-payload (e.g., deruxtecan, vedotin), not its specific antibody target. This allows for anticipating toxicities like neuropathy or GI issues based on the payload class, creating a predictable framework for management across different ADCs.

Data shows that patients who permanently stopped ipilimumab due to immune-related side effects still had exceptionally good outcomes. This gives clinicians confidence to manage toxicity by discontinuing the CTLA-4 inhibitor portion of the regimen while continuing nivolumab, without fearing a loss of efficacy.

Unlike neuropathy from vincristine which peaks during therapy, polatuzumab vedotin exhibits a "late cresting phenomenon." Patients can experience worsening neuropathy even after completing their sixth and final cycle, a crucial detail for patient counseling and proactive management.